Outlook Therapeutics
OTLK
18 hedge funds and large institutions have $27M invested in Outlook Therapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
28% more capital invested
Capital invested by funds: $21.1M → $27M (+$5.9M)
20% more funds holding
Funds holding: 15 → 18 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$793K |
| 2 |
Goldman Sachs
New York
|
+$519K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$370K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$77.5K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$40K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$254K |
| 2 |
JG
Jefferies Group
New York
|
-$240K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$235K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$213K |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$62.9K |
OTLK Hedge Fund Activity: Q3 2016 in Review
18 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2016, worth a combined $27M — up 28% from $21.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new OTLK positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Sabby Management, adding an estimated $793K. The largest seller was Perceptive Advisors, cutting an estimated $254K.
- 18 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2016, up from 15 in Q2 2016.
- Funds reported $27M of Outlook Therapeutics stock for Q3 2016, up 28% quarter-over-quarter.
- 4 funds opened new Outlook Therapeutics positions in Q3 2016 and 1 closed out, a net change of +3 holders.
- The largest Outlook Therapeutics buyer in Q3 2016 was Sabby Management, an estimated $793K added.
- The largest Outlook Therapeutics seller in Q3 2016 was Perceptive Advisors, an estimated $254K sold.
Based on aggregated 13F filings for Q3 2016.